Hemoglobinuria

(redirected from paroxysmal nocturnal hemoglobinuria)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.
Related to paroxysmal nocturnal hemoglobinuria: Paroxysmal cold hemoglobinuria

hemoglobinuria

[‚hē·mə‚glō·bə′nu̇r·ē·ə]
(medicine)
A pathological condition in which the urine contains hemoglobin.

Hemoglobinuria

 

the presence of hemoglobin in urine. It usually is a result of the intravascular decomposition of red blood cells following the transfusion of incompatible blood, the effect of some chemical and biological poisons and drugs that cannot be tolerated or of any of several causative agents of infections, extensive injuries, and so on.

References in periodicals archive ?
Hill, "The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab," Therapeutics and Clinical Risk Management, vol.
DUhrsen et al., "Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria," Blood, vol.
* The report provides a snapshot of the global therapeutic landscape of Paroxysmal Nocturnal Hemoglobinuria
Paroxysmal nocturnal hemoglobinuria. Blood 2014; 124:2804-11.
Spectrum of renal involvement in paroxysmal nocturnal hemoglobinuria: Report of three cases and a brief review of the literature.
How I treat paroxysmal nocturnal hemoglobinuria. Blood, 2009: 113(26): 6522-6527.
Red blood cell indices help us to classify anemias as microcytic, normocytic, and macrocytic depending on low, normal or high MCV.3 Most of the causes of pancytopenia present with normal RBC indices,4 but causes like megaloblastic anemia, aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria present with high MCV.5
(Nasdaq: ALXN), Cheshire, Conn., has announced positive data from the 26-week extension of the AEGIS study, an open-label registration study examining Soliris (eculizumab) for the treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH).
At age 19, Day was diagnosed with paroxysmal nocturnal hemoglobinuria, a rare blood disorder.
The pharmaceutical company derives all of its revenue from Soliris, which treats paroxysmal nocturnal hemoglobinuria (PNH).

Full browser ?